Related Experiment Video
Updated: Sep 20, 2025
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
18.2K
Oligometastatic Breast Cancer
Jonathan B Strauss1, Steven J Chmura2
1Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611.
Seminars in Radiation Oncology
|June 10, 2022
Summary
Oligometastatic breast cancer, defined by 1-5 metastases, may benefit from high-intensity focused radiation therapy (HIFRT). The SABR-COMET trial showed HIFRT improved survival compared to standard care in these patients.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Oncology
Background:
- Oligometastatic breast cancer (1-5 metastases) is an intermediate stage with a distinct molecular profile and better prognosis than widely metastatic disease.
- This limited metastatic state may be amenable to aggressive, ablative therapies targeting known disease sites.
- Current selection criteria include a disease-free interval >2 years, limited metastases, and fewer involved organs.
Purpose of the Study:
- To evaluate the efficacy of high-intensity, image-guided, robotic radiotherapy (HIGRT) in patients with oligometastatic breast cancer.
- To compare survival outcomes between HIGRT and standard of care in this patient population.
Main Methods:
- The phase II SABR-COMET trial enrolled patients with oligometastatic disease across multiple histologies.
- Patients were randomized to receive either HIGRT or standard of care treatment.
- Outcomes were assessed based on survival advantage.
Main Results:
- The study found a notable survival advantage for patients treated with HIGRT compared to the standard of care group.
- HIGRT demonstrated potential as an effective ablative therapy for oligometastatic disease.
Conclusions:
- HIGRT shows promise for improving survival in oligometastatic breast cancer.
- Ongoing trials continue to explore HIGRT's role, with future research aiming to refine patient selection using molecular signatures and clinical criteria.
